Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Expects OTC Nexium Will Launch With Market Exclusivity

This article was originally published in The Tan Sheet

Executive Summary

Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.

You may also be interested in...



P&G Portfolio Trimming ‘Full Steam Ahead’ As Currency Headwind Pummels Profit

P&G’s net income declined 31% in its second quarter and will decline for its full fiscal 2015 due to foreign exchange, but the firm remains focused on core brand growth and innovation and will weather the storm. The company so far sold or consolidated 35 of the 90 to 100 brands on its streamlining chopping block.

P&G Portfolio Trimming ‘Full Steam Ahead’ As Currency Headwind Pummels Profit

P&G’s net income declined 31% in its second quarter and will decline for its full fiscal 2015 due to foreign exchange, but the firm remains focused on core brand growth and innovation and will weather the storm. The company so far sold or consolidated 35 of the 90 to 100 brands on its streamlining chopping block.

J&J/McNeil Consent Decree Prequel Tops OTC Stories, Switch Leads Topics In 2014

“The Tan Sheet” readers also made top stories of FDA’s rejection of Bayer’s petition for aspirin as primary prevention of heart attack stroke; advisors recommending FDA consider additional label warnings for OTC NSAIDS; and FDA seeking to overhaul its OTC drug monograph process to be “more agile and responsive.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel